In a real-world multicenter study, afatinib was used to treat 20 patients with NRG1 fusion-positive lung cancers, achieving an objective response rate of 25% and a median PFS of 2.8 months [2]. It indicated that some patients with NRG1 fusions could benefit from ERBB-targeted therapy and some not. This evidence concerns the gene NRG1 and lung cancer.